The CF Foundation recently provided an update on the following research trial.

Study of Ataluren in people with CF who have a nonsense mutation and are not taking aminoglycosides

This is a phase 3, placebo controlled trial will look at the safety and effectiveness of the drug ataluren. Researchers aim to show that ataluren is effective in improving lung function and overall health in those with a CF nonsense mutation. This study is for people who are not taking an aminoglycoside like tobramycin and are over the age of 6. Participants must also be shown to have at least one copy of a nonsense mutation. This trial will require lung function tests, and blood tests.